Biomedical Engineering Reference
In-Depth Information
217. Woehlecke H, Pohl A, Alder-Baerens N, Lage H, Herrmann A. 2003. Enhanced exposure
of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC
transporter BCRP (ABCG2). Biochem J 376(Pt 2): 489-495.
218. Merino G, Jonker JW, Wagenaar E, Van Herwaarden AE, Schinkel AH. 2005. The breast
cancer resistance protein (BCRP/ABG2) affects pharmacokinetics, heptobiliary excre-
tion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67: 1758-1764.
219. Imai Y, Tsukahara S, Asada S, Sugimoto Y. 2004. Phytoestrogens/flavonoids reverse
breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:
4346-4352.
220. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE. 2001. A
functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).
Biochim Biophys Acta 1512: 171-182.
221. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. 2006. Breast
Cancer Resistance Protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and
affects their oral availability, pharmacokinetics and milk secretion. Drug Metab Dispos
34: 690-695.
222. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. 2005. Involve-
ment of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:
800-807.
223. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama SC, Baba M. 2003.
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1
nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63: 65-72.
224. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, Baba M.
2004. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the
wild-type breast cancer resistance protein. Biochem Pharmacol 68: 1363-1370.
225. Wang X, Baba M. 2005. The role of breast cancer resistance protein (BCRP/ABCG2)
in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem
Chemother 16: 213-216.
226. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan
K. 2002. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1)
effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer
Res 8: 22-28.
227. Scharenberg CW, Harkey MA, Torok-Storb B. 2002. The ABCG2 transporter is an ef-
ficient Hoechst 33342 efflux pump and is preferentially expressed by immature human
hematopoietic progenitors. Blood 99: 507-512.
228. Allen JD, van Dort S, Buitelaar M, van Tellingen O, Schinkel AH. 2003. Mouse breast
cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport,
but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:
1339-1344.
229. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM, Schinkel
AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal pene-
tration of topotecan. J Natl Cancer Inst 92: 1628-1629.
230. Minderman H, O'Loughlin KL, Pendyala L, Baer MR. 2004. VX-710 (biricodar) in-
creases drug retention and enhances chemosensitivity in resistant cells overexpressing
P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin
Cancer Res 10: 1826-1834.
Search WWH ::
Custom Search